anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I The variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in BCG vaccinated infants without tuberculosis or HIV infection. Infants (126 to 182 days) received intradermal (ID) study vaccine (MVA85A/AERAS-485 or Candida skin test antigen control). All infants were to be followed for at least 15 months after the last infant was enrolled into the study. Given completion of enrollment in 21 months, the total duration of follow-up for each infant was scheduled to be at least 15 months and up to 36 months. Infants were to be followed for the entire duration of the study both for the development of tuberculosis and serious adverse events.

On enrollment to the study, eligible infants were assigned to a study group starting with Study Group 1 and were randomized in a 1:1 ratio within a study group to receive either MVA85A/AERAS-485 or Candida skin test antigen control. Infants were assigned to a safety cohort (Study Group 1), then into 1 of 3 immunological assay evaluation groups (Study Groups 2-4), and finally the remainder of infants were assigned into the correlate of protection cohort (Study Group 5). At least 330 infants were to be randomized in Study Group 1, up to 50-60 infants each in Study Groups 2-4, and the remaining infants were randomized in Study Group 5.
Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but potentially curable cause of pulmonary hypertension (PH). Currently PH is diagnosed by right heart catheterisation. Computed tomography (CT) is used for ruling out other causes and operative planning. This study aims to evaluate importance of different quantitative/qualitative imaging features and develop a supervised machine learning (ML) model to predict hemodynamic risk groups. 127 Patients with diagnosed CTEPH who received preoperative right heart catheterization and thoracic CTA examinations (39 ECG-gated; 88 non-ECG gated) were included. 19 qualitative/quantitative imaging features and 3 hemodynamic parameters [mean pulmonary artery pressure, right atrial pressure (RAP), pulmonary artery oxygen saturation (PA SaO2)] were gathered. Diameter-based CT features were measured in axial and adjusted multiplane reconstructions (MPR). Univariate analysis was performed for qualitative and quantitative features. A random forest algorithm was trained on imaging features to predict hemodynamic risk groups. Feature importance was calculated for all models. Qualitative and quantitative parameters showed no significant differences between ECG and non-ECG gated CTs. Depending on reconstruction plane, five quantitative features were significantly different, but mean absolute difference between parameters (MPR vs. axial) was 0.3 mm with no difference in correlation with hemodynamic parameters. Univariate analysis showed moderate to strong correlation for multiple imaging features with hemodynamic parameters. The model achieved an AUC score of 0.82 for the mPAP based risk stratification and 0.74 for the PA SaO2 risk stratification. Contrast agent retention in hepatic vein, mosaic attenuation pattern and the ratio right atrium/left ventricle were the most important features among other parameters. Quantitative and qualitative imaging features of reconstructions correlate with hemodynamic parameters in preoperative CTEPH patients-regardless of MPR adaption. Machine learning based analysis of preoperative imaging features can be used for non-invasive risk stratification. Qualitative features seem to be more important than previously anticipated.
Patients receive tuvusertib PO QD on days 1-14 of each cycle and avelumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI, biopsy, and collection of blood and stool at screening and on study.
Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
PURPOSE: Investigation of pigment epithelial detachment (PED) characteristics in central serous chorioretinopathy (CSCR) is underrepresented in the literature. We present a novel computational approach to quantify PED composition indices (PEDCI) in CSCR and track changes over time.
METHODS: 34 eyes with active CSCR were analyzed quarterly over a 1-year period. Cases were categorized into acute and chronic CSCR depending on a symptom duration of less than 3 months or more than 3 months respectively. PED, retinal and choroidal dimensions were manually measured, and interval changes were compared using repeated measures of variance ANOVA. PED composition analysis involved manual segmentation followed by automated sub segmentation of PED areas to identify serous, neovascular and fibrous tissues. PEDCI for each component was compared among cases of acute and chronic CSCR.
RESULTS: CMT and NSD-h decreased by 65.2 µm (p = 0.01), and 86.5 µm (p < 0.01) respectively at 12 months. At baseline, 7/17 acute CSCR eyes and 8/15 chronic CSCR eyes had a concomitant PED; acute cases had both serous and neovascular components (PEDCI-S: 16.95%, PEDCI-N: 40.3%), whereas chronic cases only had a neovascular component (PEDCI-S: 0%, PEDCI-N: 30.5%). At 12-month follow-up, 6/7 of acute CSCR group and 6/8 chronic CSCR group had a concomitant PED; PEDCI-S was largest for acute CSCR (53.4%) and PEDCI-N was largest for chronic CSCR (46.7%).
CONCLUSION: We identify a novel biomarker PEDCI to differentiate acute and chronic CSCR with higher PEDCI-S in acute CSCR, and higher PEDCI-N in chronic CSCR.
Studies have highlighted a potential link between malignancies and immunoglobulin A nephropathy (IgAN). In such studies, the treatment of malignancy improved the symptoms of IgAN. Here, we report a patient case involving a history of hypertension, tobacco use disorder, and chronic kidney disease (CKD) presenting with hematuria with acute renal failure secondary to IgAN per renal biopsy. Prompted by this association, a malignancy workup was performed including computed tomography (CT) body imaging and biopsies of mediastinal and cervical lymph nodes which revealed a metastatic adenocarcinoma. Current knowledge includes a general mechanism behind the development of IgAN that points toward glomerular deposition of tumor-specific immunoglobulin A (IgA) immunoglobulins. However, the association of IgAN and malignancy has no definitive management guidelines. This clinical case serves as an important contribution in the hopes of future development of guidelines regarding the surveillance and management of IgAN in the setting of malignancy.
PURPOSE: A composition containing ginsenoside Rb3 is provided to ensure anti-wrinkling through molecular mechanism of fibroblast protection. CONSTITUTION: A composition for improving skin condition contains ginsenoside Rg3 as an active ingredient. A composition for skin immunomodulation contains the ginsenoside Rb3 as an active ingredient. An antioxidative composition contains ginsenoside Rb3 as an active ingredient. An anti-obesity composition contains the ginsenoside Rb3 as an active ingredient. The ginsenoside Rb3 is contained in 0.0001-10.0 wt% based on total composition. The composition is a cosmetic composition. The cosmetic composition is manufactured in a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, or spray.
A method and system for tumor ablation planning and guidance based on a patient-specific model of liver tumor ablation is disclosed. A patient-specific anatomical model of the liver and circulatory system of the liver is estimated from 3D medical image data of a patient. Blood flow in the liver and the circulatory system of the liver is simulated based on the patient-specific anatomical model. Heat diffusion due to ablation is simulated based on a virtual ablation probe position and the simulated blood flow in the liver and the venous system of the liver. Cellular necrosis in the liver is simulated based on the simulated heat diffusion. A visualization of a simulated necrosis region is generated and displayed to the user for decision making and optimal therapy planning and guidance.
Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
PURPOSE:To provide a nervous growth factor biosynthesis-accelerating agent containing nicotine as an active ingredient, promoting the biosynthesis of a nervous growth factor existing in brains and useful for treating Alzheimer's disease and for improving cerebral functions. CONSTITUTION:The agent contains the D-isomer, L-isomer or racemic of nicotine as an active ingredient. A phenol fraction in the combustion smoke tar of cigarette has a nervous growth factor biosynthesis-accelerating activity, and 1,2,4- trihydroxybenzene, 2-isopropylhydroquinone, esculetin and chlorogenic acid contained in the phenol fraction have also the same action. Further, the nicotine has the high nervous growth factor biosynthesis-accelerating action. The agent can be compounded with a conventional medical carrier and prepared into oral administration tablets or nicotine-containing gums. The active ingredients exist also in the cigarette before smoked and can be injected in the state of the leaves of the tobacco, e.g. by smoking in the form of cigarette or by chewing in the form of chewing tobacco, etc.
Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
This research corresponds to an experimental study, a randomized single-blind controlled clinical trial, in which a total of 118 individuals, both men and women aged over 65, will participate. They will be divided into four groups: the control group (n = 31) and three experimental groups (n = 29 each). The variables will be measured for both groups using the same validated tools and evaluated by the same assessor to prevent information biases and differential misclassification. Evaluations will occur at the start of the intervention and immediately after its completion, with the results recorded in a data log. Subsequently, these results will be consolidated into an Excel database, with each participant assigned a code to ensure privacy while allowing for the necessary comparability.

Regarding the independent variables, we will address sociodemographic characteristics, clinical history, and the socio-familial assessment scale. As for the outcome variables, they are categorized into several areas: those related to health status will assess the relative risk of death due to comorbidity using the Charlson Comorbidity Index, health-related quality of life using the SF36 questionnaire, and Fried's frailty phenotype. Physical condition variables will be evaluated using the Senior Fitness Battery, gait and balance using the Tinetti Scale, and gait speed with the 6-minute walk test. Functional variables will be assessed using the Katz Index (activities of daily living), the Lawton \& Brody Index (instrumental activities of daily living), and Siu and Reuben's Physical Scale (advanced activities of daily living). For the cognitive variable, we will employ the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Attention and executive functions will be measured using the Trail Making Test Part A and Part B. Verbal fluency will be assessed with the Verbal Fluency Test (VFT), while selective attention and concentration will be evaluated using the D2 test. Processing speed will be determined through the Digit Symbol Substitution Test (DSST).
Subjects will have 1 hospitalization. The visit will require hospitalization for about 24 hours. After the screening (visit 1), the subject will receive Primaquine (PQ) 30 mg base single dose at first admission (visit 2). Assessment of the safety profile will be done after admission by the investigating team before proceeding to the regimen.

The study will enroll 10 healthy obese subjects (Body mass index \[BMI\] ≥30 kg/m2) both male and female, age 18-60 years, from the pharmacokinetic unit at Faculty of Tropical Medicine, Mahidol University. Participants will be healthy HIV-1, hepatitis B and C uninfected individuals who comprehend the purpose of the study and have provided written consent. Participants will be screened and eligibility will be based on inclusion and exclusion criteria. If all doses are completed without replacement of subjects, the total number of subjects in this study is 10. All subjects will undergo screening assessments within 7 days prior to the single dose to determine their eligibility for enrollment into the study.
MFG-based consists of 16 sessions focused on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. Core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
The present invention relates to an anti-allergic composition which comprises Bacillus amyloliquefaciens subsp. plantarum or a fermented soybean substance using Bacillus amyloliquefaciens subsp. plantarum as an active ingredient. The Bacillus amyloliquefaciens subsp. plantarum or the fermented soybean substance using Bacillus amyloliquefaciens subsp. plantarum of the present invention is excellent for promoting Th1 cellular response and inhibiting Th2 cellular response, thereby can adjust balance of Th1/Th2 immune response.
Avermectins, as a new type of environmental pollutant, have received significant attention in recent years. Previous research has shown that acute exposure to avermectins can induce oxidative stress and inflammation in non-target fish species, such as carp. Flavonoid lignans, particularly Silybin, have demonstrated promising biological activities, including regulation of non-alcoholic fatty liver and cerebral ischemia-reperfusion injury. This study aims to investigate the impact of dietary supplementation with Silybin on the intestinal damage in carp caused by chronic exposure to avermectins and to improve the health status and production of carp in aquaculture. Silybin was used as a dietary supplement by adding it to the experimental feed, and an animal experimental model was utilized to assess its effects on oxidative stress, inflammation, and cell apoptosis in carp intestine. Additionally, intestinal barrier integrity, digestive capacity, and fish growth were evaluated. The results indicated that dietary supplementation with Silybin effectively alleviated the oxidative stress induced by chronic exposure to avermectins in carp intestine. Furthermore, Silybin improved intestinal barrier integrity and digestive capacity by modulating the Nrf2/Keap1 pathway. This study demonstrates that dietary supplementation with Silybin can effectively mitigate the intestinal damage caused by chronic exposure to avermectins in carp, providing a sustainable solution for the aquaculture industry to enhance the overall health and production of cultured fish. The research expands our understanding of avermectin environmental pollution and offers a potential remediation approach.
PCT No. PCT/JP92/00423 Sec. 371 Date Oct. 7, 1993 Sec. 102(e) Date Oct. 7, 1993 PCT Filed Apr. 6, 1992 PCT Pub. No. WO92/17166 PCT Pub. Date Oct. 15, 1993.A sustained release capsule excellent in adhesion characteristics in the gastrointestinal tract, stability and so on is provided. The capsule is characterized in that a polymer excellent in initial adhesion and a polymer excellent in shape-retaining ability are dispersed in a liquid substance in the capsule, that a physiologically active substance is dispersed or dissolved in the liquid substance and that the moisture content in the whole preparation is not more than 2%.
The control group will only be provided with a self-study pictorial module, and they will be tracked and requested to visit the center at the 6 months (child age) post-delivery. At 6 months, their data on responsive interactions, parenting confidence, and patient experience will be collected.
PURPOSE:To obtain the subject food and drink having excellent remedy effect with drinking and without surgery containing papain and citric acid. CONSTITUTION:1 pt.wt. papain is mixed with 0.05-20 pts.wt., preferably 0.5-5 pts.wt. and the mixture is contained in the aimed food and drink in an amount of 0.5-20wt.%, preferably 5-10wt.% of the total food and drink. Said food and drink is effective for remedy of various gynecological diseases such as hysteromyoma, descensus uteri or prolapse of the uterus. Furthermore, effect is exhibited to eliminate body smell or halitosis of human or animal.
OBJECTIVE: To assess the reporting quality of published RCT abstracts regarding patients with endometriosis pelvic pain and investigate the prevalence and characteristics of spin in these abstracts.
METHODS: PubMed and Scopus were searched for RCT abstracts addressing endometriosis pelvic pain published from January 1st, 2010 to December 1st, 2023.The reporting quality of RCT abstracts was assessed using the CONSORT statement for abstracts. Additionally, spin was evaluated in the results and conclusions section of the abstracts, defined as the misleading reporting of study findings to emphasize the perceived benefits of an intervention or to confound readers from statistically non-significant results. Assessing factors affecting the reporting quality and spin existence, linear and logistic regression was used, respectively.
RESULTS: A total of 47 RCT abstracts were included. Out of 16 checklist items, only three items including objective, intervention and conclusions were sufficiently reported in the most abstracts (more than 95%), and none of the abstracts presented precise data as required by the CONSORT-A guidelines. In the reporting quality of material and method section, trial design, type of randomization, the generation of random allocation sequences, the allocation concealment and blinding were most items identified that were suboptimal. The total score for the quality varied between 5 and 15 (mean: 9.59, SD: 3.03, median: 9, IQR: 5). Word count (beta = 0.015, p-value = 0.005) and publishing in open-accessed journals (beta = 2.023, p-value = 0.023) were the significant factors that affecting the reporting quality. Evaluating spin within each included paper, we found that 18 (51.43%) papers had statistically non-significant results. From these studies, 12 (66.66%) had spin in both results and conclusion sections. Furthermore, the spin intensity increased during 2010-2023 and 38.29% of abstracts had spin in both results and conclusion sections.
CONCLUSION: Overall poor adherence to CONSORT-A was observed, with spin detected in several RCTs featuring non-significant primary endpoints in obstetrics and gynecology literature.
The present invention relates to an oral solid preparation which comprises omeprazole. The oral solid preparation is a stomach dissolved rapid release preparation which is composed of omeprazole, antacid sodium bicarbonate and medical supplementary materials. The sodium bicarbonate can increase pH value in the stomach. The omeprazole which is extraordinarily unstable to acid is not degraded by acid. Therefore the preparation according to the invention can quicken the onset time of omeprazole without being prepared into enteric-coated preparation. The dosage ratio between omeprazole and sodium bicarbonate can keep a reasonable medicine-taking dosage of sodium bicarbonate thereby keeping a proper pH value in the stomach and reducing the adverse effect of sodium bicarbonate.
Maturity-onset diabetes of the young (MODY) is an uncommon monogenic type of diabetes mellitus. Detecting genetic variants for MODY is a necessity for precise diagnosis and treatment. The majority of MODY genetic predisposition has been documented in European populations and a lack of information is present in Iranians which leads to misdiagnosis as a consequence of defects in unknown variants. In this study, using genetic variant information of 20,002 participants from the family-based TCGS (Tehran Cardiometabolic Genetic Study) cohort, we evaluated the genetic spectrum of MODY in Iran. We concentrated on previously discovered MODY-causing genes. Genetic variants were evaluated for their pathogenicity. We discovered 6 variants that were previously reported in the ClinVar as pathogenic/likely pathogenic (P/LP) for MODY in 45 participants from 24 families (INS in 21 cases, GCK in 13, HNF1B in 8, HNF4A, HNF1A, and CEL in 1 case). One potential MODY variant with Uncertain Risk Allele in ClinVar classification was also identified, which showed complete disease penetrance (100%) in four subjects from one family. This is the first family-based study to define the genetic spectrum and estimate the prevalence of MODY in Iran. The discovered variants need to be investigated by additional studies.